Serum Biochemical Markers and Newer’s Ratios in Predicting the Short Term Outcomes in Children Undergoing Kasai’s Portoenterostomy

Roshan Sneithith¹, Divya Prakash², Narasimha K.N.³

¹Department of Paediatric Surgery, Amrita Institute of Medical Sciences, Kochi, Kerala, India. ²Department of Paediatric Surgery, Ram Manohar Lohia Institute of Medical Sciences, Lucknow, Uttar Pradesh, India. ³Department of Paediatric Surgery, Indira Gandhi Child Health Hospital and Research Centre, Bangalore, Karnataka, India.

ABSTRACT

BACKGROUND
Biliary Atresia (BA) is described as an obliterator cholangiopathy of progressive type resulting in fibrosis and cirrhosis of liver. The proxy marker utilized to detect fibrosis of liver is the aspartate aminotransferase to platelet ratio index (APRI) in liver disorder cases and in biliary atresia affecting old children. The study therefore was done to evaluate the role of simple composite indices like Alanine aminotransferase (ALT) to Platelet index (ALPRI), INR / Platelet ratio in predicting the short-term outcomes in terms of 6-month bilirubin clearance < 2 mg / dL.

METHODS
This was a longitudinal cohort study conducted over a period of 22 months, in the Department of Paediatric Surgery at Amrita Institute of Medical Sciences, Kochi. The study group comprised of 40 consecutive biliary atresia children who underwent Kasai’s portoenterostomy (KPE) between 2016 and 2018 in whom various routine serum biochemical markers were studied and APRI, ALPRI, INR / Platelet ratio were studied. Demographic information including gender, age in months at the time of Kasai operation, date of surgery, biochemical parameters included serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), albumin, total bilirubin, direct bilirubin, r- glutamyl - transpeptidase (GGT), alkaline phosphatase, platelet count, prothrombin time / INR (International Normalised Ratio), TORCH (Toxoplasmosis, Rubella, Cytomegalovirus and HSV) panel. Each variable was reviewed prior to surgery and then after 2 weeks, third month and after 6 months of KPE. Early cholangitis was defined as hyperpyrexia (38.0 °C) along with serum total bilirubin, leukocytosis with left shift, and normal to acholic stools within 6 months after KPE. SPSS 22.0 version (IBM) was employed for statistical assessment. ROC analysis, Chi square tests were employed.

RESULTS
Using a cut-off value of APRI > 0.45 [AUC 0.731 (95 % CI 0.542 – 0.931)] a sensitivity of 78 % and a specificity of 69.2 % for clearance of jaundice at 6 months was seen. APRI at 3 months > 0.505 [(AUC 0.82 (95 %CI)] a sensitivity of 77.8 % and specificity of 76.9 % was seen. Above mentioned cut-off APRI at 2 weeks and 3 months correlated with persistence of jaundice (p<0.05). Median ALPRI was 0.53 (0.04-3.52); using cut-off value of ALPRI > 0.610 (AUC 0.78) showed 79.4 % sensitivity and 76.2 % specificity) at 2 weeks post-operatively and it correlated with persistence of jaundice (p<0.05). APRI at 3 months postoperatively with cut-off <= 0.98 showed better survival prediction (p<0.05).

CONCLUSIONS
APRI and ALPRI have shown their usefulness as a noninvasive tool, which has provided with means to predict clearance of jaundice and mortality as short term outcome much earlier than in comparison to conventional biochemical parameters.

KEYWORDS
Biochemical Markers, Mortality, Bilirubin, Biliary Atresia
Biliary Atresia (BA) is a rare, life threatening liver disorder with limited prognosis affecting infants. Biliary atresia is seen in 1 in 10,000 and 1 in 16,700 live births, with occurrence being higher in Asians.\(^1,2\) It is characteristic of progressive obstructive cholangiopathy which affects both intra- and extrahepatic biliary ducts.\(^3\) The precise cause of biliary atresia remains blurred and poses a multifactorial origin. Models proposing genetic, inflammatory, and infectious etiologies are presented,\(^4\) but remains non – conclusive.\(^5\)

Hepatic portoenterostomy or Kasai operation is regarded as conventional therapy for decades.\(^6,7\) In Kasai's portoenterostomy (KP) the atretic extra hepatic mass was removed, and a Roux – en - Y jejunal loop was anastomosed to the hepatic hilum. Among good prognostic Portoenterostomy, the flow of bile could be brought back to normal with clearance of jaundice. Yet, BA cases undergoing Kasai intervention present an uncertain prognosis. Though the surgery enhances prognostic rates, greater number of cases might still need transplantation in their latter part of lives.\(^8\) Factors determining prognosis are intervention employed and outcomes of operation. In case of not performing portoenterostomy, fibrosis gets progressed inevitably into final stage cirrhosis and eventually death in first year in about 50 – 80 % of child population and about 90 – 100 % cases in third year.\(^9\)

In regards to lab values, aspartate aminotransferase – to - platelet ratio index (APRI) is employed to analyse fibrosis of liver in cases affected by BA and is suggestive of predictive parameter of native liver survival (NLS).\(^10\) Aspartate Platelet ratio index (APRI) stands as illustration of a non-invasive biochemical marker based on restricted cost and universal available option, presumed to reflect the degree of intrahepatic fibrosis.\(^11\)

We hypothesize that simple composite indices like INR/platelet ratio, APRI, ALPRI, AST / ALT ratio (AAR) can prognosticate effectively the short term outcome in terms of jaundice clearance and help in becoming a better tool in counselling the parents of infants with Biliary atresia. The aim of this study is to illuminate on current data in the literature regarding current understanding of biliary atresia and role of biochemical markers and the APRI, ALPRI, AST / Platelet index, AST / ALT ratio, INR / Platelet index in predicting the short term outcomes in terms of bilirubin clearance by 6 months post-surgery.

## Statistical Analysis

Statistical analysis was run utilising IBM SPSS version 20.0 software. (Chicago SPSS Inc., Chicago, IL, USA) Categorical variables are expressed using frequency and percentage. Numerical variables are presented using mean and standard deviation. ROC curve was used to find ideal cut-off for APRI at 2 weeks, 3 months, 6 months and ALPRI for predicting at
2 weeks to predict bilirubin clearance. ROC curve was also used for finding the ideal cut-off for the variables- bilirubin, and APRi at 3 months and ALPRi for predicting mortality. Chi-Square test with continuity correction was done to find the association of APRi and ALPRi with bilirubin clearance and mortality. p value <0.05 is considered to be statistically significant.

RESULTS

There were 17 females and 23 males; their median age at the time of Kasai operation was 63.5 days (37 - 150) days. Preoperative laboratory parameters assessed just prior to surgery of the cohort showed S total bilirubin with median of 18.1 mg / dL (with a range of 5.9 - 21) mg / dL and Gamma glutamyl transpeptidase with mean of 660 IU / L with median of 644. Preoperative INR was with median of 1.1 (range 0.8 - 3.4), Platelet count median of 481.5 x 10^3 / ml. INR platelet ratio with mean of 1.30 and APRi with median of 0.58 and ALPRi 0.53.

Table 1 shows the association of APRi at different intervals and ALPRi at 2 wks, post operatively with Clearance of Bilirubin. Post - operatively 3 months, 21 patients (87.5 %) have non clearance of bilirubin with APRi at >=0.505 three months postoperatively, and 3 patients (12.5 %) have clearance / Jaundice free, which shows statistical significance with p value 0.003. After 6 months, out of 37 patients, 6 patients (75 %) have bilirubin clearance / jaundice free with APRi at <0.27 six months postoperatively, and 2 patients (25 %) have non clearance / Persistent Jaundice which shows statistical significance with p value 0.024.

The Area under curve is 0.760 with 95 % confidence interval, the cut-off of APRi at 6 months post operatively 0.270 has sensitivity of 91.7 % and specificity of 46.2 % and cut off more than 0.9950 has a sensitivity of 50 % with specificity of 100 % in non - clearance of jaundice (Figure 1). Receiver operator characteristics (ROC) curve for ALPRi at 2 weeks for the determination of Bilirubin clearance by 6 months (Figure 2). The area under ROC curve is 0.782 with 95 % confidence interval, the cut-off of ALPRi at 2 wks, post operatively 0.610 has sensitivity of 79.4 % and specificity of 76.2 % bilirubin clearance at 6 months of age (Table 2).

Out of 40 patients, 19 patients (100 %) were alive by 6 months with S bilirubin at 2 wks. < 8.13 mg / dL and none were dead when S bilirubin was < 8.13 mg / dL which shows statistical significance with p value 0.009. Survival prediction for patients with APRi < .98 which shows statistical significance with p value 0.003 (Table 3).

13 of the patients who were jaundice free showed change in mean APRi of 0.0815 ± 0.51 from preoperative values and assessment at 6 months, whereas bilirubin non clearance group (n = 24) patients showed change in APRi at mean of 0.1850 ± 1.09 which was not statistically significant, p value 0.408 (Graph 2).
The prognostic outcome of chronic cholestatic diseases is dependent partially on the extent of fibrosis in liver. Although liver biopsy is the gold standard method for the determination of liver fibrosis, it is invasive and also, the distribution of fibrosis in liver parenchyma is heterogeneous. Due to these limitations, APRI was developed as an alternative. APRI is an indirect biochemical marker of hepatic fibrosis 23 on the basis of widespread availability and routinely done laboratory parameters reflecting the change in hepatic fibrosis.

Our study is the first, to validate the composite indices of ALPRI, APRI, INR / Platelet ratio in assessing the bilirubin clearance (BC) and short term outcomes with a cohort of BA infants from Kerala (South India). In our study S bilirubin at two weeks postoperatively is a simple and logical predictor for outcome in BA. The cut - point of 8.13 mg / dL was determined by area under curve of 0.805 with 95 % CI with sensitivity of 100 % and specificity of 60%. Patients with S bilirubin < 8.13 mg % at 2 weeks showed 100% survival for 6 months duration (p<0.05). It is found in our study that S bilirubin 2 weeks postoperatively after KP makes a reasonable grade depicting moderate flow of bile. Of the greater benefits employing these markers is that clinician might educate the cases attendants about the outcome probability in 2 weeks post surgically and the 1st post-operative visit, as in case of our department protocol. It helps in early counselling of patients who will require liver transplantation.

It was noted in our study that those patients with an APRI > 0.45 at 2 weeks postoperatively and APRI at 3 months with >0.505 have high chance of persistence of jaundice by 6 months of age (p<0.05). This was independently established in these patients. Similarly the other composite index, ALPRI at 2 weeks with patients having ALPRI >0.610 have a higher chance of persistence/non clearance of bilirubin (p<0.05).

In our study, patients with S bilirubin <8.1 mg / dL at 2 weeks have 100% survival at six months of age (p<0.05), which corresponds to good bile drainage. APRI calculated at 3 months postoperatively, patients with value<0.98 have better survival at 6 months (p<0.05). It was observed in our study group that 93 % of patients who were alive had APRI <0.98. It was also observed in our study group that BA children with ALPRI >2.1 at 3 months had mortality at six months with sensitivity of 100 %. Out of the 5 patients who lost the native liver (mortality / liver transplant) by six months post KP (2 transplant patients), 3 were found to have high APRI and ALPRI by 2 weeks and 3 months. This gives impetus to the hypothesis that APRI and ALPRI are fairly reliable indicator of progression of the disease and can be used as early as 2 weeks post operatively.

Yang LY et al12 revealed that greater counts of platelets and lesser AST grades on clinical presentation was correlated with a greater effect among infants suffering from BA. It was also noted that by multiple regression analysis both variables were independent of each other. Following which, the composite index APRI was formed presumably independently utilising both variables but validated greatly in chronic liver disease in adults. Dos Santos de Oliveira et al13 and Chusilp S et al14 showed that APRI was significantly correlated to METAVIR fibrosis scores in children with hepatitis C. APRI, ALPRI, AST / ALT, INR / Platelet ratio has the advantage of requiring only three routine laboratory tests (LFT, CBC, INR). Davenport et al15 have also demonstrated the usefulness of APRI in children with biliary atresia and have shown that APRI at the time of KP is a useful indicator in assessing grading of liver disease. There is scanty literature available on simple composite indices like...
ALPRI, INR / Platelet ratio and ALT / AST ratio in predicting the outcomes in biliary atresia.

The present assessment has demonstrated that clearance of jaundice wasn't obtained in any child with an initial APRI of >3.0, and additionally all would have needed liver transplant to survive. This lends weight to our impression that this indeed is a better indicator of the status of the liver at the time of presentation. This study hence validates APRI and ALPRI as an useful adjunct tool in evaluating the severity of disease in BA at presentation and immediate post-operative period and on early follow up, hence helps in counselling the parents on the prognosis of the disease.

Limitations
1. Follow up period was short.
2. Sample size was limited as it was a pilot study
3. A prospective study with longer follow-up would have enabled us to substantiate the findings of our study with respect to the native liver survival and 5-year mortality.

CONCLUSIONS

In our study, APRI and ALPRI have shown their usefulness as noninvasive tools, which have provided with means to predict clearance of bilirubin and mortality at 6 months, much earlier, in comparison to conventional biochemical parameters.

Financial or Other Competing Interests: None.

REFERENCES

[1] Sanghai SR, Shah I, Bhatnagar S, et al. Incidence and prognostic factors associated with biliary atresia in western India. Ann Hepatol 2009;8(2):120-122.

[2] Poddar U, Thapa BR, Das A, et al. Neonatal cholestasis: differentiation of biliary atresia from neonatal hepatitis in a developing country. Acta Paediatr 2009; 98(8):1260-1264.

[3] Hartley JL, Davenport M, Kelly DA. Biliary atresia. Lancet 2009;374(9702):1704-1713.

[4] Kim S, Seok J, Han S, et al. Assessment of liver fibrosis and cirrhosis by aspartate aminotransferase -to-platelet ratio index in children with biliary atresia. J Pediatr Gastroenterol Nutr 2010;51(2):198-202.

[5] Grieve A, Makin E, Davenport M. Aspartate aminotransferase- to- platelet ratio index (APRI) in infants with biliary atresia: prognostic value at presentation. J Pediatr Surg 2013;48(4):789-795.

[6] Kasai M, Suzuki S. A new operation for non-correctable biliary atresia: hepatic portoenterostomy. Shujutsu 1959;13:733-739.

[7] Kasai M, Kimura S, Asakura Y, et al. Surgical treatment of biliary atresia. J Pediatr Surg 1968;3(6):665-675.

[8] Dreyzin A, Lunz J, Venkat V, et al. Long-term outcomes and predictors in pediatric liver retransplantation. Pediatr Transplant 2015;19(8):866-874.

[9] Ramachandran P, Safwan M, Reddy MS, et al. Recent trends in the diagnosis and management of biliary atresia in developing countries. Indian Pediatr 2015;52(10):871-879.

[10] Kim SY, Seok JY, Han SJ, et al. Assessment of liver fibrosis and cirrhosis by aspartate aminotransferase-to-platelet ratio index in children with biliary atresia. J Pediatr Gastroenterol Nutrition 2010;51(2):198-202.

[11] Lind RC, Verkade HJ, Porte RJ, et al. Aspartate transaminase- to- platelet ratio index is not correlated with severity of fibrosis or survival in children with biliary atresia. J Pediatr Gastroenterol Nutr 2012;54(5):698.

[12] Yang LY, Fu J, Peng XF, et al. Validation of aspartate aminotransferase to platelet ratio for diagnosis of liver fibrosis and prediction of postoperative prognosis in infants with biliary atresia. World J Gastroenterol 2015;21(19):5893-5900.

[13] de Oliveira FDS, Kieling CO, dos Santos JL, et al. Serum and tissue transforming [corrected] growth factor β1 in children with biliary atresia. J Pediatr Surg 2010;45(9):1784-1790.

[14] Chusilip S, Sookpotarom P, Tepmalai K, et al. Prognostic values of serum bilirubin at 7th day post-Kasai for survival with native livers in patients with biliary atresia. Pediatr Surg Int 2016;32(10):927-931.